Economic Evaluation of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer in the United States.

Breast cancer (Dove Medical Press)（2022）

引用 4|浏览3

暂无评分

摘要

The cost-effectiveness analysis suggested that, at current price, trastuzumab deruxtecan is unlikely to be a preferred option for patients with HER2-low breast cancer at a threshold of $150,000/QALY from a US payer perspective.

查看译文

关键词

HER2-low breast cancer,cost-effectiveness,partitioned survival approach,trastuzumab deruxtecan

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要